RBC Capital reiterates Axon stock rating on growth outlook By Investing.com

Axon: RBC reiterated Outperform with a $735 price target and projects roughly $6.0B in revenues and 28% EBITDA margins by FY28; company reported ~33% revenue growth over the last 12 months and ~60% gross margin. TD Cowen raised its PT to $950 citing 53% Q4 bookings growth and fiscal 2026 guidance beat, while Craig-Hallum and BofA trimmed targets to $820 and $700 respectively amid valuation/sector selloff concerns. Shares trade at $372.87, down ~49% over six months and near the 52-week low of $362.73, with InvestingPro calling the stock undervalued and analysts maintaining a consensus Buy.

Analysis

Axon’s core advantage is structural: sensor-led data ownership plus a public-safety workflow spine creates high incremental gross margins on additional software and AI attachments. That lever converts one-time hardware wins into multi-year annuity-like cashflows and makes unit economics highly sensitive to camera/drone attach rates and ARPU per device.

Second-order beneficiaries include edge-AI silicon and camera-imager suppliers, plus cloud/CDN capacity for secure forensic storage; conversely, legacy hardware incumbents that rely on license refresh cycles and do not monetize data will see margin share erosion. Procurement timing is the gating variable — municipal budget and tender cycles create lumpy revenue recognition that can amplify quarter-to-quarter volatility despite smooth long-run economics.

Key risks are timing and execution, not pure product-market fit: a miss in non-US deployments, slower drone-commercial adoption, or a headline privacy/chain-of-custody incident could compress multiples quickly. Monitor three high-leverage KPIs over the next 6–18 months — revenue per device (or ARR/1000 devices), international bookings cadence, and AI-attachment conversion — to tell whether margin expansion and re-rating are actually being realized rather than merely priced in by sentiment.

Key Decisions for Investors

• Tactical long via options: Buy a 12-month call spread on AXON sized to 1.5% of fund NAV (buy longer-dated ATM LEAP, sell ~20% OTM call). Rationale: captures multi-quarter ARR re-rating while capping premium. Target 3x payoff if attachment metrics accelerate; cut to 50% or unwind if company misses guidance on bookings or ARPU.
• Paired relative express trade: Long AXON equity (1.0% NAV) / short IGV software ETF (1.0% NAV) for 6–12 months. Rationale: isolates company-specific lift from sector multiple compression; expected relative outperformance 30–50% if Axon converts hardware to high-margin software. Stop-loss: 20% absolute move against either leg or concurrent market-wide risk-on that inflates both.
• Supply-chain play: Long Ambarella (AMBA) for 6–12 months (0.5% NAV) to play increased edge-AI inference demand from bodycam/drone growth. Risk/reward: asymmetric upside if edge inference adoption accelerates; monitor ASP and win-rate news from major integrators and exit on slower-than-expected design wins.
• Insurance dial: Buy 3–6 month protective puts on AXON equal to ~30% notional when implied vol spikes > historical 90-day median. Use as short-term hedge around municipal budget season and earnings; cost is small insurance against headline/regulatory shocks that would force rapid re-pricing.